Related Experiment Video
Updated: Jan 16, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Metabolic Dysfunction Associated to Steatotic Liver Disease: A Review
Janna Vanessa Diaz Torres1, Vanessa Rocío Villanueva Guerrero1, Jennifer Patricia Vargas Gómez1
1Internal Medicine Program, Faculty Of Health, Exact And Natural Sciences, Universidad Libre, Barranquilla, Colombia.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition affecting over a third of the global population, particularly those with obesity. This review details the new nomenclature, diagnosis, and treatment of MASLD.
Area of Science:
- Hepatology
- Metabolic Disorders
- Clinical Medicine
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) replaces nonalcoholic fatty liver disease, emphasizing its link to metabolic issues.
- MASLD is characterized by hepatic steatosis and metabolic risk factors like type 2 diabetes and obesity.
- It affects over 33% of the global population, being more common in men.
Purpose of the Study:
- To provide a comprehensive clinical overview of MASLD.
- To explain the nomenclature change from NAFLD to MASLD.
- To familiarize readers with MASLD diagnosis and treatment.
Main Methods:
- Review of current literature on MASLD.
- Discussion of diagnostic imaging (elastography, MRI) and biomarkers.
- Analysis of treatment strategies including lifestyle modifications and emerging therapies.
Main Results:
- MASLD is a complex condition influenced by environmental, genetic, and epigenetic factors.
- Accurate diagnosis involves imaging and serological markers, with elastography and MRI being key for fibrosis assessment.
- Lifestyle changes, including diet and exercise, are primary treatments, with promising pharmacological options under investigation.
Conclusions:
- The shift to MASLD terminology aims to reduce stigma and better define the condition.
- Early diagnosis and intervention, focusing on metabolic health, are crucial for managing MASLD.
- Ongoing research into pharmacological treatments offers hope for improved patient outcomes.
More Related Videos
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
07:12Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
Published on: June 2, 2023
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug